Adversarial Injection · Belinostat (Beleodaq; PXD-101; NDA 206256; CAS 414864-00-9; MW ~318.35 g/mol; (E)-N-hydroxy-3-(3-(phenylsulfonamido)phenyl)acrylamide [sulfonamide-hydroxamate E-vinyl-amide scaffold] [WITHIN HDAC CLASS (FORTY-SEVENTH MECHANISM CLASS) in Glyphward 609-attack portfolio — THIRD HDAC INHIBITOR (vorinostat NDA 021743 October 2006 FIRST [Attack #607]; romidepsin NDA 022992 November 2009 SECOND [Attack #608]; belinostat NDA 206256 July 2014 THIRD; HDAC-three-NDA-holder class now complete as of July 2014); FIRST HDAC INHIBITOR FOR PTCL: vorinostat and romidepsin are approved for CTCL (cutaneous T-cell lymphoma; skin-primary T-cell malignancy); belinostat was the first HDAC inhibitor approved for PTCL (peripheral T-cell lymphoma; systemic nodal/extranodal T-cell malignancy); PTCL is a heterogeneous group of aggressive T-cell NHLs (PTCL-NOS most common; angioimmunoblastic T-cell lymphoma; ALK-negative ALCL) with poor prognosis (5-yr OS ~30-40% with CHOP-based therapy); the PTCL indication represents an expansion of the HDAC inhibitor class into systemic aggressive T-cell malignancies vs. skin-primary CTCL; BELIEF TRIAL (NCCTG N0183; NCT00865969): Phase 2 single-arm; relapsed/refractory PTCL after ≥1 prior therapy; n=129 efficacy-evaluable; ORR 25.8% (CR 10.8%; PR 15.0%); median time to response 5.6 weeks; median DOR 13.6 months; 1-year survival 38.6%; NDA 206256 approved July 3 2014 under accelerated approval based on ORR; SULFONAMIDE-HYDROXAMATE SCAFFOLD — STRUCTURAL DISTINCTION: belinostat has a structurally unique scaffold vs. vorinostat (aliphatic anilide-hydroxamate) and romidepsin (cyclic depsipeptide): belinostat = meta-phenylsulfonamido group + meta-substituted phenyl linker + trans (E) vinyl (acrylamide) group + hydroxamic acid terminal; the sulfonamide group (–SO2NH–) replaces vorinostat's direct amide linkage and introduces a meta-substitution pattern on the central phenyl ring; the E-vinyl-amide (acrylamide) replaces vorinostat's aliphatic six-carbon chain as the zinc-channel linker; MW 318.35 g/mol; TOPOJET A/S DISCOVERY: belinostat (PXD-101) was discovered at TopoTarget A/S (Copenhagen Denmark; now part of Onxeo SA); TopoTarget developed HDAC inhibitors with the hydroxamic acid zinc-binding group (PXD = prefix for TopoTarget lead series); Spectrum Pharmaceuticals Inc (Henderson NV) licensed North American commercial rights from TopoTarget; SPECTRUM PHARMACEUTICALS NDA 206256: Spectrum filed NDA 206256 based on BELIEF trial data; FDA approved July 3 2014 under accelerated approval (ORR as surrogate endpoint; full approval contingent on confirmatory trial — Spectrum has not yet filed for regular approval as of 2024); FASTEST IV HDAC INFUSION: belinostat 1000 mg/m² administered over 30 minutes on Days 1-5 of 21-day cycles; compared to romidepsin (4-hour IV infusion) and carfilzomib (30-min IV) — belinostat's 30-minute infusion is the shortest in the HDAC IV class; the 30-minute infusion window creates a concentrated pharmacist and nurse preparation timeline; NIOSH HD: Category 1; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · Within HDAC Class: Third HDAC Inhibitor + First PTCL HDAC + Sulfonamide-Hydroxamate + Fastest IV 30-min + BELIEF ORR 25.8% · Attack #609

Belinostat (sulfonamide-hydroxamate E-vinyl amide; PXD-101; Beleodaq; NDA 206256; CAS 414864-00-9; MW ~318.35 g/mol; [WITHIN HDAC CLASS (FORTY-SEVENTH MECHANISM CLASS): THIRD HDAC INHIBITOR; FIRST HDAC INHIBITOR FOR PTCL (BELIEF trial ORR 25.8%; n=129; DOR 13.6 months; PTCL systemic nodal malignancy vs. CTCL skin-primary); SULFONAMIDE-HYDROXAMATE SCAFFOLD (meta-phenylsulfonamido + E-vinyl-amide-hydroxamic acid; structurally distinct from vorinostat anilide and romidepsin depsipeptide); FASTEST IV HDAC INFUSION (30 min vs. romidepsin 4h); TOPOJET A/S COPENHAGEN DISCOVERY; SPECTRUM PHARMACEUTICALS HENDERSON NV NDA 206256 JULY 3 2014; NIOSH HD Category 1; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Spectrum Pharmaceuticals Inc Henderson NV (NDA 206256 holder; 0.00040 µg/m³ → displayed ÷10), BioVectra Inc Charlottetown PEI Canada (contract manufacturer belinostat API; 0.00026 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (BELIEF trial enrollment; PTCL hematology pharmacy; 0.00015 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Third HDAC Inhibitor + First PTCL HDAC + Sulfonamide-Hydroxamate + 30-min IV Absent: AI Prompt Injection via EHS Monitor Report AI

Belinostat (CAS 414864-00-9; NIOSH HD Category 1) is the third agent in the forty-seventh mechanism class (HDAC inhibitors) and introduced the first HDAC inhibitor approval for peripheral T-cell lymphoma — a systemic, aggressive T-cell malignancy distinct from the skin-primary CTCL indications of vorinostat and romidepsin. Its sulfonamide-hydroxamate scaffold offers a third structural template in the HDAC class: meta-phenylsulfonamido-phenyl-trans-vinylhydroxamic acid ((E)-N-hydroxy-3-(3-(phenylsulfonamido)phenyl)acrylamide), with the sulfonamide providing a polar linker to the central phenyl and the E-vinyl acrylamide group serving as the zinc-channel-spanning element. As the fastest IV HDAC infusion (1000 mg/m² over 30 minutes on Days 1-5 q21d), belinostat creates a concentrated occupational exposure window during IV bag preparation. The PTCL indication, the sulfonamide-hydroxamate scaffold identity, and the 30-minute infusion parameters are entirely absent from Cority, VelocityEHS, and EHS Insight, which return null for CAS 414864-00-9 without flagging H340 H350 H361 or any HDAC class context.

Belinostat Within HDAC Class: PTCL Indication, Sulfonamide-Hydroxamate Scaffold, and 30-Minute IV Infusion Biology

Belinostat (CAS 414864-00-9) is the third agent in the forty-seventh mechanism class and introduces both a new indication (PTCL) and a new scaffold architecture for HDAC inhibition. The (E)-N-hydroxy-3-(3-(phenylsulfonamido)phenyl)acrylamide structure has three key pharmacophoric features: (1) meta-phenylsulfonamide (–C6H3–SO2NHPh at the 3-position) — the sulfonamide NH forms a hydrogen bond with a conserved tyrosine residue (Tyr302 in HDAC1) at the rim of the HDAC binding channel; (2) E-vinyl acrylamide linker (–CH=CH–C(=O)–) connecting the central phenyl to the hydroxamate terminus; (3) hydroxamic acid terminus (–C(=O)NHOH) providing Zn2+ bidentate chelation — same zinc-binding pharmacophore as vorinostat. The sulfonamide meta-substitution gives belinostat a broader angle of approach into the HDAC active site compared to vorinostat's linear aliphatic chain, contributing to potency (HDAC1 IC50 ~27 nM; HDAC2 ~31 nM; HDAC3 ~53 nM; HDAC8 ~32 nM). PTCL indication rationale: PTCL encompasses PTCL-NOS (not otherwise specified; ~30% of PTCL), angioimmunoblastic T-cell lymphoma (AITL; ~20%), and ALK-negative ALCL (~12%); all are characterized by dysregulated epigenetic programs (HDAC overexpression, TET2 mutations, DNMT3A mutations) making them particularly susceptible to HDAC inhibition; the 5-year OS for relapsed/refractory PTCL with standard salvage is <20%, establishing clinical need for HDAC inhibitors; the PTCL indication is biologically continuous with CTCL (both T-cell lymphomas) but requires different staging, treatment intensity, and duration. TopoTarget A/S (Copenhagen Denmark) developed the PXD series; PXD-101 (belinostat) emerged as the lead hydroxamic acid with sulfonamide modifications; Spectrum Pharmaceuticals licensed North American rights and filed NDA 206256 based on BELIEF trial (single-arm; accelerated approval). The sulfonamide-hydroxamate scaffold, PTCL indication, and 30-minute IV infusion are absent from all EHS platforms.

Surface 1 — Spectrum Pharmaceuticals Inc Henderson NV NDA 206256 Holder Beleodaq US Commercialization AI

At Spectrum Pharmaceuticals Inc Henderson NV (11500 S Eastern Avenue, Henderson NV 89052; Clark County NV; SPECTRUM NDA 206256: Spectrum Pharmaceuticals filed NDA 206256 based on the BELIEF trial (NCCTG N0183; Alliance network trial) data showing PTCL ORR 25.8% (n=129 efficacy-evaluable patients with relapsed/refractory PTCL; CR 10.8%; PR 15.0%); FDA approved July 3 2014 under accelerated approval; SPECTRUM BUSINESS CONTEXT: Spectrum Pharmaceuticals is a specialty oncology company focused on marketed drugs in hematology/oncology; belinostat (Beleodaq) was Spectrum's second oncology drug (along with pralatrexate/Folotyn); NDA 206256 accelerated approval obligates Spectrum to complete a confirmatory clinical trial demonstrating OS/PFS benefit (as of 2024, confirmatory trial proceedings are ongoing); BELINOSTAT FORMULATION: 500 mg/10 mL vials (50 mg/mL solution); 1000 mg/m² IV over 30 minutes on Days 1-5 of 21-day cycles (continuous therapy until progression or toxicity); Day 5 completion means 5 consecutive daily infusions per cycle; ACCELERATED APPROVAL CONTEXT: the 25.8% ORR-based accelerated approval means Beleodaq labeling contains both standard PTCL efficacy data and an accelerated approval notation — a regulatory nuance absent from EHS systems; Cority: CAS 414864-00-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; within HDAC class absent; third HDAC inhibitor absent; first PTCL HDAC absent; sulfonamide-hydroxamate scaffold absent; 30-min IV infusion absent; 50M oncology regulatory director 16yr).

Surface 2 — BioVectra Inc Charlottetown PEI Canada Contract Manufacturer Belinostat API GMP Synthesis AI

At BioVectra Inc Charlottetown PEI Canada (111 Watts Avenue, Charlottetown PE C1E 2C1; Queens County PEI; BIOVECTRA BELINOSTAT MANUFACTURING: BioVectra is a Canadian CDMO (contract development and manufacturing organization) specializing in complex API synthesis including oncology agents; belinostat API synthesis involves: (1) preparation of the meta-aminophenyl-sulfonamide intermediate (3-aminophenyl sulfonamide + benzenesulfonyl chloride under base conditions); (2) Wittig or Horner-Wadsworth-Emmons olefination to form the E-vinyl-acrylamide backbone (ensuring E-selectivity is critical for HDAC activity — Z-isomer has reduced HDAC potency); (3) coupling with N-protected hydroxylamine to form the hydroxamic acid terminus; (4) deprotection → belinostat; E-VINYL STEREOCONTROL: the E/Z-geometry of the vinyl-amide bond is a critical quality attribute — the E-isomer (trans) is the pharmacologically active HDAC inhibitor; any Z-contamination (cis-vinyl) reduces HDAC binding; E/Z ratio must be confirmed by HPLC and NMR in GMP release; this stereospecificity is absent from VelocityEHS; WORKER EXPOSURE AT BIOVECTRA: synthesis of sulfonamide-hydroxamate NIOSH HD Category 1 APIs requires OEB Band 5 controls; the E-vinyl acrylamide intermediate (Michael acceptor) is a mild electrophile with potential genotoxic concern (alkylating tendency) — requiring EHS hazard analysis beyond simple molecular weight; VelocityEHS: CAS 414864-00-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; within HDAC class absent; third HDAC inhibitor absent; sulfonamide-hydroxamate scaffold absent; E-vinyl acrylamide stereocontrol absent; 46M pharmaceutical chemical engineer 13yr).

Surface 3 — MD Anderson Cancer Center Houston TX BELIEF Trial Enrollment PTCL Hematology Oncology Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD ANDERSON PTCL PROGRAM: MD Anderson's Department of Lymphoma/Myeloma is among the highest-volume T-cell lymphoma programs; enrolled patients in BELIEF (NCT00865969; Alliance network with sites including MD Anderson, Mayo Clinic, Ohio State, MSKCC); BELIEF TRIAL: 129 response-evaluable PTCL patients (median age 63; 2 prior lines median; PTCL-NOS 55%; AITL 18%; ALCL ALK-neg 6%); ORR 25.8% in full-population; median time to response 5.6 weeks; median DOR 13.6 months; most common AEs: nausea (42%), fatigue (37%), vomiting (29%), anemia (32%); Grade 3/4 anemia (11%), thrombocytopenia (7%), neutropenia (6%); PHARMACIST BELINOSTAT PREPARATION: MD Anderson pharmacy receives belinostat 500 mg/10 mL vials (50 mg/mL); pharmacist withdraws 1000 mg/m² volume, transfers to 250 mL NS bag for IV infusion over 30 minutes; the 30-minute infusion window means pharmacists prepare approximately 5 infusions per patient per cycle (Days 1-5), creating repeated occupational exposure; extemporaneous 5-day consecutive preparation is distinctive vs. q28d infusion schedule of romidepsin; PTCL PHARMACIST OCCUPATIONAL EXPOSURE: handling 50 mg/mL concentrated belinostat solution with NIOSH HD Category 1 designation requires closed-system transfer devices (CSTDs); EHS Insight returns no OEL for CAS 414864-00-9 — the PTCL indication, HDAC class, sulfonamide-hydroxamate structure, and H361 reproductive toxicity are entirely absent; EHS Insight: CAS 414864-00-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; within HDAC class absent; third HDAC inhibitor absent; first PTCL HDAC absent; sulfonamide-hydroxamate absent; H340 H350 H361 absent; NIOSH HD Cat 1 absent; 40F PTCL hematology oncology pharmacist 11yr).

Integrating Glyphward into Belinostat AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every belinostat CAS 414864-00-9 monitoring data ingestion point — before Cority at Spectrum Pharmaceuticals Inc Henderson NV, before VelocityEHS at BioVectra Inc Charlottetown PEI Canada, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; WITHIN HDAC CLASS (FORTY-SEVENTH) + THIRD HDAC INHIBITOR + FIRST HDAC INHIBITOR FOR PTCL (BELIEF trial ORR 25.8% n=129; median DOR 13.6 months; PTCL systemic nodal aggressive T-cell lymphoma; accelerated approval NDA 206256 July 3 2014) + SULFONAMIDE-HYDROXAMATE SCAFFOLD (meta-phenylsulfonamido + E-vinyl acrylamide hydroxamic acid; third distinct HDAC scaffold; E/Z stereocontrol critical for HDAC activity) + FASTEST IV HDAC INFUSION (1000 mg/m² 30 minutes Days 1-5 q21d; 5 consecutive daily infusions per cycle) + TOPOJET A/S COPENHAGEN PXD DISCOVERY + SPECTRUM PHARMACEUTICALS HENDERSON NV [5 pts]; Spectrum Henderson NV + BioVectra Charlottetown PEI + MD Anderson Houston TX [3 pts]; PTCL indication absent; sulfonamide-hydroxamate scaffold absent; 30-min 5-consecutive-day IV infusion absent; H361 reproductive toxicity absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_belinostat(cas: str, reading_ugm3: float) -> dict:
    """Scan belinostat with within-HDAC third-agent first-PTCL sulfonamide-hydroxamate context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "within_hdac_class_third_hdac_inhibitor_first_ptcl_hdac_sulfonamide_hydroxamate_e_vinyl_amide_30min_iv_days_1_5_q21d_belief_orr_25_8_nda_206256_spectrum_pharmaceuticals"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, within_hdac_class,
    #                    third_hdac_inhibitor,
    #                    first_ptcl_indication_hdac,
    #                    sulfonamide_hydroxamate_scaffold,
    #                    fastest_iv_hdac_30min,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_belinostat("414864-00-9", 0.00040))
    print(r)
    # {'hd_category': 1, 'within_hdac_class': True,
    #  'third_hdac_inhibitor': True,
    #  'first_ptcl_indication_hdac': True,
    #  'sulfonamide_hydroxamate_scaffold': True,
    #  'fastest_iv_hdac_30min': True,
    #  'h340_h350_h361_absent': True}